Co-immunotherapy with interleukin-2 and taurolidine for progressive metastatic melanoma.

Irish Journal of Medical Science
G C O'BrienHenry P Redmond

Abstract

Recombinant interleukin-2(rIL-2) therapy in metastatic melanoma is limited by toxicities, particularly vascular leak syndrome(VLS). Taurolidine potentiates the anti-neoplastic effects of IL-2 while reducing its associated endothelial cell dysfunction in experimental settings. We hypothesized that co-administration of rIL-2 with taurolidine could enhance tolerability without weakening effectiveness. Eleven patients with progressive metastatic melanoma received high-dose rIL-2 with co-infusion of taurolidine. Patients were monitored for the development of toxicities and evidence of response. Ten patients tolerated twenty-nine courses of high-dose rIL-2 without dose-reduction. Most toxicities were low-grade. No patient developed VLS. Seven patients died from disease progression. Two had complete clinical and radiological responses to treatment. Two patients remain alive despite evidence of disease progression a mean of 17.5 months after diagnosing metastatic disease. Co-administration of taurolidine with high-dose rIL-2 in stage IV melanoma patients appears to greatly enhance the tolerability of this regime without diminishing its therapeutic value.

References

Jan 1, 1992·Physiological Reviews·R J Huxtable
Jul 1, 1994·The British Journal of Surgery·D M BakerJ D Hardcastle
Jan 1, 1997·Langenbecks Archiv für Chirurgie·K H Staubach
May 20, 1998·Seminars in Surgical Oncology·S M Sharpless, T K Das Gupta
Jul 14, 1998·JPEN. Journal of Parenteral and Enteral Nutrition·B JurewitschK Jeejeebhoy
Feb 22, 2001·European Surgical Research. Europäische Chirurgische Forschung. Recherches Chirurgicales Européennes·H AbdihS Kearns
Oct 31, 2002·Seminars in Oncology·Lawrence E Flaherty, Shirish M Gadgeel
Jul 16, 2003·International Immunopharmacology·Malcolm S Mitchell
Aug 28, 2003·Cancer Immunology, Immunotherapy : CII·Malcolm S Mitchell
Aug 29, 2003·Expert Opinion on Investigational Drugs·Anna C PavlickAmanda Bailes
Jul 21, 2004·Clinics in Dermatology·Kathryn Spanknebel, Howard L Kaufman
Sep 24, 2004·Archives of Surgery·Richard EssnerDonald L Morton

❮ Previous
Next ❯

Citations

Dec 30, 2009·Annals of Surgical Oncology·Peter M NearyHenry P Redmond
Jan 28, 2015·International Journal of Oncology·Kamran HaratiAdrien Daigeler
Feb 28, 2008·European Surgical Research. Europäische Chirurgische Forschung. Recherches Chirurgicales Européennes·C BraumannC A Jacobi
Dec 3, 2016·Molecular Medicine Reports·Kamran HaratiMustafa Becerikli
Aug 13, 2017·BMC Pharmacology & Toxicology·René FahrnerAlexander S Mosig

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.